^
Association details:
| Biomarker: | PD-L1 overexpression + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer
Published date:
02/14/2022
Excerpt:
Our findings suggest that KRAS mutations combined with PD-L1high expression is a better predictive biomarker than only PD-L1high for response to first-line immunotherapy with pembrolizumab in patients with stage IV NSCLC.
Secondary therapy:
Immunotherapy
DOI:
10.1101/2021.11.27.21266822v2
Source:
Title:
KRAS G12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (>=50%) lung adenocarcinoma
Excerpt:
...PD-L1 expression was higher in KRAS-positive patients (75% vs. 65%, P=0.13). Objective response rate (ORR), median progression-free survival (PFS) and overall survival (OS) in the KRAS G12C group (n=32, 51.6%) were 63.3%, 19.8 months (mo.) and not estimable (NE), respectively. Results in KRAS other and wild type patients were similar and by far lower (42.7%, P=0.06; 6.2 mo., P<0.001; 23.4 mo., P=0.08).
DOI:
10.21037/tlcr-20-958
